The RNA population (transcriptome) generated by Pol II transcription of mammalian genomes can be characterized by various next-generation sequencing technologies 1,2 . Very often total RNA-seq is used, which provides information predominantly about steady-state RNA, largely comprising mature isoforms. As a result, information on RNA processing events coupled to Pol II transcription-such as pre-mRNA splicing and premiRNA processing 3-5 -is lacking in total RNA-seq profiles. RNA processing is orchestrated by the extended CTD of the Pol II large subunit that comprises a heptad amino acid sequence (consensus YSPTSPS) repeated 52 times 6 . Although Pol II CTD is highly phosphorylated during transcription, the relationship between co-transcriptional RNA processing and CTD phosphorylation is poorly understood.
IntroDuctIon
The RNA population (transcriptome) generated by Pol II transcription of mammalian genomes can be characterized by various next-generation sequencing technologies 1, 2 . Very often total RNA-seq is used, which provides information predominantly about steady-state RNA, largely comprising mature isoforms. As a result, information on RNA processing events coupled to Pol II transcription-such as pre-mRNA splicing and premiRNA processing [3] [4] [5] -is lacking in total RNA-seq profiles. RNA processing is orchestrated by the extended CTD of the Pol II large subunit that comprises a heptad amino acid sequence (consensus YSPTSPS) repeated 52 times 6 . Although Pol II CTD is highly phosphorylated during transcription, the relationship between co-transcriptional RNA processing and CTD phosphorylation is poorly understood.
Several different techniques have been described that generate profiles of extremely unstable nascent RNA in eukaryotes ( Table 1) . In particular, global nuclear run-on sequencing (GRO-seq) and precision nuclear run-on sequencing (PRO-seq), using modified nucleotides, have mapped transcriptionally engaged Pol II occupancy and revealed Pol II pausing 7, 8 . Similarly, the 3′ ends of nascent RNA isolated from insoluble chromatin have been sequenced at high resolution 9, 10 . Finally, native elongating transcript sequencing (NET-seq), achieved by immunoprecipitation (IP) of flag-tagged Pol II, generates genome-wide nascent RNA maps in yeast 11 and bacteria 12 . However, these techniques have not so far provided nascent transcription profiles linked to either Pol II CTD modifications or to RNA processing. To enable us to generate such profiles, we recently developed and published an advanced NET-seq method for mammalian cells, termed mammalian NET-seq 13 (mNET-seq, see Fig. 1 ); this protocol is based on those published methods.
Development of mNET-Seq
Originally, NET-seq was established in yeast 11 and used to isolate and sequence RNA in the Pol II active site by a Pol II IP approach. In essence, this technique involves cryogenic breakage of the yeast cell wall to allow the preparation of a crude whole-cell extract.
Pol II complexes are immunoprecipitated from this extract using anti-FLAG antibodies against endogenous FLAG-tagged Rpb3. To extend the NET-seq approach to mammalian cells, we first isolate native chromatin using 1 M urea and 300 mM NaCl, as this fraction is enriched for nascent RNA and phosphorylated Pol II (ref. 14) . After solubilization of chromatin by extensive micrococcal nuclease digestion, we then immunoprecipitated specific Pol II complexes from this chromatin fraction. Independently, Churchman and colleagues have also developed a so-called NET-seq method for human cells 10 . However, their method does not use IP of Pol II complexes, but instead it detects the 3′ end of chromatin-associated RNA, potentially including some degraded RNA. Consequently, our mNET-seq procedure is the only available method to profile Pol II CTD phosphorylation-specific nascent RNA genome-wide.
Consistent with previous nascent RNA-seq studies, mNETseq detects both sense and antisense transcripts at transcription start sites (TSS), especially when using the 8WG16 Pol II antibody (specific for unphosphorylated CTD) 13 . Indeed, mNET-seq and GRO-seq give closely matching nascent RNA profiles ( Supplementary  Fig. 1 ). Interestingly, a splicing intermediate is readily detected by IP with Ser5-P CTD-specific Pol II antibody. This suggests that 5′ exons when cleaved by spliceosome are tethered to Pol II with Ser5-P-modified CTD 13 . Thus, mNET-seq provides comprehensive data not only on the precise Pol II occupancy of nascent RNA but also on RNA processing intermediates across the genome. chromatin into a soluble fraction. Only RNA protected by protein complexes such as Pol II or the spliceosome will be resistant to MNase digestion. Pol II complex-associated nascent RNA fragments are purified from solubilized chromatin by Pol II IP using Pol II antibodies with different specificities. Consequently, Pol II modification-specific nascent RNA profiles are obtained. The 5′ hydroxyl (OH) generated by MNase digestion of RNA is converted to a 5′ phosphate by T4 polynucleotide kinase (PNK) treatment to allow 5′ linker ligation, whereas the 3′ linker is ligated to the 3′ OH end of the RNA present within the Pol II active site, thus enabling directional sequencing. Radioactive ATP (γ-32 P ATP) is also used in the PNK reaction to facilitate size selection on denaturing polyacrylamide gels of 35-to 100-nt RNA before subsequent adapter ligation, PCR-based preparation of the cDNA sequencing library and multiplexed Illumina sequencing. The sequence readout can be bioinformatically aligned to the human genome sequence to effectively map all RNA 3′ ends. Note that co-transcriptional cleavage of 5′ splice sites (SS) additionally results in RNA 3′ OH ends that are protected by the spliceosome and are co-immunoprecipitated with Pol II, thus contributing to the mNET signal. It should also be emphasized that mNET-seq detects both protein-coding gene nascent transcripts and long noncoding RNA derived from intergenic regions.
Bioinformatic analysis allows the genomic alignment of nascent RNA profiles at single-nucleotide resolution. This effectively defines both the exact positions of elongating Pol II across the genome and the precise RNA cleavage positions of some co-transcriptional RNA processing factors. Remarkably, we can directly detect the initial 5′ SS cleavage step in pre-mRNA splicing and also observe active Drosha cleavage of pre-miRNA hairpin structures that are present in gene introns in a Pol II CTD phosphorylation-dependent manner 13 . Thus, the use of Pol II antibodies recognizing the full range of different CTD modifications will allow mNET-seq technology to uncover the highly complex CTD code of Pol II transcription.
Advantages of mNET-seq
mNET-seq is the only currently available method that allows examination of genome-wide nascent transcript profiles on the basis of Pol II CTD phosphorylation status and coupled RNA processing. The key features of this technique are as follows.
No cross-linking. No cross-linking is used, as the elongating Pol II complex is stable in chromatin 14, 16, 17 . Other techniques such as chromatin immunoprecipitation (ChIP) and in vivo cross-linking immunoprecipitation (CLIP) experiments require prior crosslinking (formaldehyde treatment for ChIP and UV cross-linking for CLIP) to examine DNA-protein and RNA-protein interactions. However, such cross-linking procedures may introduce artifactual interactions.
Chromatin digestion. MNase is a very efficient nuclease with little digestion bias on active chromatin regions, but it leaves the native Pol II complex intact. Furthermore, it is easy to inactivate by EGTA treatment. A short digestion time (90 s in our method) is used to minimize Pol II complex dissociation and consequent degradation of Pol II-protected RNA.
Pol II IP. Different Pol II-specific antibodies ( Table 2) can be used in mNET-seq to explore Pol II modification-specific nascent RNA processing. For example, in our Ser5-P CTDspecific mNET-seq analysis, Pol II accumulation on cotranscriptionally spliced exons and a splicing intermediate tethered to the Pol II complex are detected. Furthermore, Ser2 and Ser5-P CTD-specific mNET-seq detects intermediates generated by co-transcriptional microprocessor-mediated cleavage 13 . Limitations of mNET-seq Some of the limitations of this technique are as follows:
In mNET-seq, 35-to 100-nt RNA fragments are selected and sequenced. Consequently, nascent RNAs shorter than 35 nt (i.e., those within 35 bp of the TSS) cannot be profiled. In theory, smaller fragments could also be selected, sequenced and mapped by extending the lower limit to 20 nt. However, this may result in the loss of unique sequence alignment 18 . In addition, it has been estimated that only nascent RNA longer than 15-17 nt extrudes from Pol II, to become accessible to 5′ capping enzymes 19 ( Table 2 ), a 1-h incubation was identified as optimal for obtaining the maximum yield of Pol II complex under our IP conditions; this is a sufficiently short time period to avoid nonspecific IP products. However, some Pol II antibodies may be less efficient in Pol II IP, in which case longer incubations (>1 h) may be required. In this case, potent RNA inhibitors such as SUPERase-In (Thermo, cat. no. AM2696) should be added to the IP reaction buffer to prevent RNA degradation. mNET-seq provides the genomic position of nascent RNA 3′ ends. Therefore, both elongating Pol II occupancy and RNA cleavage events, such as pre-mRNA splicing and pre-miRNA processing, can be determined. However, as Pol II-associated complexes, such as the spliceosome and microprocessor, can also give rise to RNA cleavage peaks, we were unable to distinguish whether individual mNET-seq peaks reflected Pol II accumulation or co-transcriptional RNA cleavage. It is possible that more stringent washing of the IP sample may allow separation of RNA processing-derived RNA 3′-ends from elongating Pol II. RNA 3′ ends in the Pol II active site could then be unambiguously determined in the mNET-seq profile. mNET-seq shows Pol II distribution over a gene, with higher peaks at a specific location suggesting Pol II pausing. However, peaks might also arise from PCR bias that could dominate the true profile during library amplification. The use of a low number of PCR cycles (<15 cycles) to amplify the cDNA library is crucial to minimizing this effect. Primer bands should be detected on 6% (wt/vol) polyacrylamide gels when gel purification is performed as an indication that the PCR reaction is unsaturated. Addition of random nucleotides (barcodes) to the 3′ ends of RNA inserts before sequencing adapter ligation might help identify and remove PCR duplication problems 10 . We use gentle MNase digestion conditions on the chromatin pellet to avoid overdigestion of Pol II-associated RNA. A possible limitation is that not all Pol II complexes are released under these conditions. However, a comparison between GRO-seq and mNET-seq suggests that mNET-seq detects virtually all engaged Pol II (Pearson's correlation coefficient = 0.93, P < 2.2e−16, See Supplementary Fig. 1 ). We predict that undigested chromatin reflects mostly heterochromatic regions of the genome that are untranscribed, or that have low levels of transcription. However, it is possible that more potent nuclease treatment may be required to allow fuller recovery of Pol II complexes from chromatin.
Application of mNET-seq
We have so far used a variety of Pol II antibodies for mNET-seq ( Table 2) , which has allowed us to reveal genome-wide nascent
transcription, as well as coupled RNA processing. In theory, a range of biological questions could be addressed by using other antibodies for mNET-seq. Antibodies specific to transcription factors and RNA processing factors associated with elongating Pol II could be used to determine where these factors are involved in Pol II elongation and pausing. In addition, Pol I and III antibodies would reveal nascent transcription maps for these separate polymerases. Nascent RNA profiles specifically associated with Pol II mutants (such as the kinetically slow Pol II and various Pol II CTD mutants) could be obtained by ectopically expressing tagged-Pol II mutants in cells, and performing IPs with antibodies specific to the tag.
Although we have analyzed nascent RNA in the elongating Pol II complex selected by specific Pol II antibodies, we have not analyzed other protein components of the complex. To understand which proteins are associated with particular co-transcriptional events using particular Pol II modifications, it will be important to examine all the proteins in the specific Pol II IP by mass spectrometry. It is also possible to compare mass spectrometry profiles using specific conditions, such as transcription elongation inhibition, to better understand which factor is important for the effect.
Experimental design
Chromatin and nascent RNA digestion. Before proceeding to a large-scale experiment, some of the mNET-seq cDNA library preparation stages should be carefully checked and optimized. First, digesting insoluble chromatin and nascent RNA is a crucial step. Even though MNase is a very efficient nuclease, its activity may sometimes vary. In particular, when using different cell lines, the optimal MNase concentration should be recalibrated by titrating MNase levels and by checking the efficiency of Pol II release from insoluble chromatin by western blotting. In addition, overly harsh MNase digestion could affect nascent RNA length. Determination of RNA length on denaturing gels after Pol II IP is recommended. To do this, radiolabel the mNET-seq RNA preparation using T4 PNK and γ-32 P ATP, and check that the MNase digestion gives the expected smear pattern on a denaturing 8% (wt/vol) polyacrylamide gel (Fig. 2a) .
Cell lines.
It is important to test cell lines or tissue before mNETseq, as their behavior in the protocol may vary. Before starting an experiment, cell fractionation and Pol II immunoprecipitated RNA recovery should be tested. HeLa 13 and A549 (T.N., T.G., M.C.-F. and N.J.P., unpublished data) cells have been successfully used for mNET-seq by our group. However, the nucleus and chromatin pellet of A549 cell are much smaller than those of HeLa cells. Consequently, a lower MNase concentration (which depends Tested Pol II antibodies are described. ELISA data and mNET-seq data are available 13 .
on chromatin pellet size) is required for A549 cells. Normally, 1.0 × 10 8 cells provides a good read coverage across the human genome in mNET-seq. Although the coverage level will be lower, 2.5 × 10 7 cells are sufficient for highly expressed genes. Transcription activity is different in each cell so that the minimum required cell number should be tested for each cell line.
Controls. The IP step is critical. IP efficiency and the specificity of the antibody should be checked by western blotting. An ideal IP efficiency is >50%. Immunoprecipitated RNA should be checked on a denaturing gel. Mock IPs (in which antibody is omitted from the IP reaction) or IPs using mouse IgG are useful negative controls; neither Pol II protein nor Pol II-associated RNA should be detected by western blotting or on denaturing gels, respectively 13 , for these controls. For mNET-seq, a mouse monoclonal antibody is preferable to a rabbit polyclonal antibody, as the latter may display significant lot variation. HLB+NS HLB+NS is 10 mM Tris-HCl (pH 7.5), 10 mM NaCl, 2.5 mM MgCl 2 , 0.5% (vol/vol) NP-40 and 10% (wt/vol) sucrose. 1 ml of HLB+NS is required for each preparation; for 30 cell fractionations, prepare 50 ml as follows. Add 0.5 ml of 1 M Tris-HCl (pH 7.5), 100 µl of 5 M NaCl, 125 µl of 1 M MgCl 2 , 2.5 ml of 10% (vol/vol) NP-40 and 10 ml of 50% (wt/vol) sucrose to 36.725 ml of autoclaved distilled water.  crItIcal Always use autoclaved distilled water, and after mixing filter the solution using a MILLEX GP 0.22 µm. Just before use, add 1× Complete proteinase inhibitor Urea dye Urea dye is 7 M urea, 0.05% (wt/vol) xylene cyanol and 0.05% (wt/vol) bromophenol blue. 10 µl of urea dye is required for each sample; for 1,000 samples, prepare 10 ml as follows. Add 4.2 g of urea, 0.5 ml of 1% (wt/vol) xylene cyanol and 0.5 ml of 1% (wt/vol) bromophenol blue and then fill up to 10 ml with nuclease-free water.  crItIcal Store it at room temperature for up to 1 year. 5× Ficoll dye 5× Ficoll dye is 15% (wt/vol) Ficoll-400 and 0.05% (wt/vol) bromophenol blue. 12 µl of 5× Ficoll dye is required for each sample; for 800 samples, prepare 10 ml as follows. Add 1.5 g of Ficoll-400 and 0.5 ml of 1% (wt/vol) bromophenol blue, and then fill up to 10 ml with nuclease-free water.  crItIcal Store it at room temperature for up to 1 year. 
5|
Incubate the mixture on a tube rotator (12 r.p.m.) in a cold room for at least 1 h or overnight.
6| Wash the Dynabeads with 1 ml of ice-cold NET-2 buffer by vortexing at room temperature: repeat this step twice (total three times).
7|
Replace the wash buffer with 100 µl of ice-cold NET-2 buffer. Place on ice until use (see Step 25).
cell fractionation • tIMInG 1 h  crItIcal Steps 8-16 should be performed in the cold room. 8| Wash the cells from Step 1 with 20 ml of ice-cold PBS twice and, using a scraper, collect the cells into a 10-ml tube.  crItIcal step Use one 10-ml tube for each dish from Step 1.
9|
Centrifuge the cells at 420g for 5 min at 4 °C, and then discard the supernatant to collect the cell pellets.
10|
Resuspend the cells with 4 ml of ice-cold HLB+N and incubate the samples on ice for 5 min.
11| By using a 1-ml pipette, underlay the cell pellet with 1 ml of ice-cold HLB+NS.  crItIcal step Prepare ~1.5 ml of HLB+NS for each sample. Add the solution under the resuspended cells slowly so as not to disturb the layer.
12|
Centrifuge the cells at 420g for 5 min at 4 °C, and then discard the supernatant to collect the nuclear pellets.  crItIcal step Remove white debris in the supernatant, as that is possibly cytoplasmic membrane.
13|
Add 125 µl of ice-cold NUN1 buffer to the nuclear pellet, resuspend by pipetting and transfer the sample to a new 1.5-ml microcentrifuge tube.
14| Add 1.2 ml of ice-cold NUN2 buffer and then vortex it at maximum speed to mix.
15|
Incubate the samples on ice for 15 min.  crItIcal step Vortex the samples every 3-4 min. You should see white chromatin pellets in this step.
16|
Centrifuge the samples at 16,000g for 10 min at 4 °C, and then discard the supernatant to collect the chromatin pellets.
chromatin and rna digestion • tIMInG ~5 min 17| Add 100 µl of MNase buffer to the chromatin pellets from Step 16.  crItIcal step Do not try to resuspend, as the pellet cannot be broken until MNase is added. ? troublesHootInG 18| Centrifuge the samples at 16,000g for 10 s at 4 °C, and then discard the supernatant to collect the chromatin pellets.
19| Add 100 µl of MNase reaction mixture to the pellet. The volumes per sample are given below. 
22|
Centrifuge the samples at 16,000g for 5 min at 4 °C.
23|
Take 100 µl of supernatant from each sample and mix them together (total 600-800 µl).  crItIcal step Be careful not contaminate with the pellet, as this may result in background signals.
24| Dilute the pooled sample from
Step 23 with 6-8 ml of ice-cold NET-2 buffer.  crItIcal step This tenfold dilution helps prevent protein aggregation and nonspecific binding.
25|
Add Pol II antibody-conjugated beads (600-800 µl for each sample pooled at Step 23) from Step 7 and mix immediately.  crItIcal step Add mouse IgG or no antibody beads to separate samples for negative control.
26|
Incubate the samples on a tube rotator (12 r.p.m.) for 1 h in the cold room.  crItIcal step Do not incubate for longer than 1 h, as this may cause RNA degradation.
27|
Spin the samples at 300g for 5 min at 4 °C and discard the supernatant.
28|
Transfer the beads to a 1.5-ml microcentrifuge tube.  crItIcal step ~1 ml of supernatant should be retained to enable this transfer.
29|
Place the tube on a magnetic rack and leave it for 1 min. Remove the remaining supernatant.
30| Wash the beads with 1 ml of ice-cold NET-2 buffer by inverting tube, and repeat Steps 29 and 30 seven times (total eight times) in the cold room, taking care to remove the supernatant after the final wash.
rna phosphorylation with t4 pnK • tIMInG 10 min 31| Resuspend the beads in 300 µl of ice-cold PNKT buffer.  crItIcal step Transfer 15 µl of sample to a new tube for monitoring RNA size by the incorporation of radioactivity during phosphorylation (Step 33); this sample is processed alongside the experimental sample in Steps 32-49.
32|
Place the tubes on a magnetic rack and leave them for 1 min. Remove the supernatant.
33|
Resuspend the beads in 200 µl of PNK reaction mixture, as tabulated in the first table below. For the size-monitoring sample, resuspend the beads in 10 µl of the reaction mix tabulated in the second table below. ! cautIon Always be careful when working with radioactive materials. Consult local and institutional rules for detailed guidelines.
34|
Incubate the samples at 37 °C for 6 min at 1,400 r.p.m. on a thermomixer.
35|
36| Wash the beads with 1 ml of ice-cold NET-2 buffer by inverting the tube. Place the tubes on a magnetic rack and leave them for 1 min. Remove the supernatant.
purification of rna • tIMInG 45 min 37| Add 1 ml of TRIzol reagent to the beads and mix them well by vortexing.
38|
Incubate the mixture for 5 min at room temperature.  pause poInt The samples can be stored for a few weeks at −20 °C.
39|
Add 200 µl of chloroform and mix well by vortexing.
40|
Incubate the samples for 2 min at room temperature.
41|
Spin the samples at 16,000g for 15 min at 4 °C.
42|
Place the new tubes on the magnetic rack and add 1 µl of GlycoBlue co-precipitant.
43|
Transfer 500 µl of upper phase from tubes in Step 41 into a new tube on the rack.
44|
Add 500 µl of isopropanol and mix it well by vortexing.
45|
Incubate the samples for 10 min at room temperature.
46|
Spin the samples at 16,000g for 10 min at 4 °C.
47|
Discard the supernatants completely using a pipette.
48| Dry the samples with the lid open for 3 min at room temperature.
49|
Dissolve the pellets in 10 µl of urea dye.
rna size fractionation • tIMInG 8 h 50| Apply the samples from Step 49 to a denaturing 8% (wt/vol) polyacrylamide gel containing 7 M urea.  crItIcal step Use a sequencing gel (200 × 380 mm, 0.5 mm) to ensure proper separation of bands.  crItIcal step The radiolabeled sample (usually >2,000 c.p.s.) should be applied to the same gel. There must be at least two empty lanes between radiolabeled and unlabeled samples to avoid radioactive cross-contamination of the mNET-seq sample. It is also useful to include a radiolabeled DNA size marker (~2,000 c.p.s.) for size calibration; we recommend MspI-digested pBR322 for this purpose.
51|
Run the gel in 1×TBE buffer for 30 min at 30 W.  crItIcal step Regulate by wattage, as voltage will change during the electrophoresis.
52|
Take the plates apart and cover the gel with Sarogold wrap.
53|
Expose the gel to Super RX, Fuji medical X-ray film for 5 min at room temperature, and then develop the film. ? troublesHootInG 54| Place the developed film on the gel and mark the 35-to 100-nt size on Sarogold wrap with a marker pen.  crItIcal step Normally, 35-to 100-nt RNAs lie between the two dyes (xylene cyanol and bromophenol blue) in 8% (wt/vol) urea gel. Signals should be a smear (Fig. 2a) .
55|
Cut the gel and place the gel slices into a new 1.5-ml microcentrifuge tube.  pause poInt The gel fragments can be frozen for several weeks at −80 °C.
56|
Add 400 µl of RNA elution buffer to the gel slices from
Step 55, and then crush the gel with a 1-ml plastic syringe.
57|
Elute the RNA by rotating it for 2 h at room temperature.
58|
Centrifuge the sample at 16,000g for 10 s at room temperature.
59|
Transfer 400 µl of supernatants to a spin-X column, which has two glass filters on the membrane.
60|
Centrifuge the tube at 16,000g for 1 min at room temperature.
61|
Transfer the flow-through to a new 1.5-ml microcentrifuge tube.
62|
Add 0.5 µl of GlycoBlue co-precipitant and 1 ml of 100% ethanol.  pause poInt The samples can be stored at −20 °C.
63| Repeat the elution (Steps 57-62).
 crItIcal step The first-and second-round elutes should not be combined in this step: keep them in different tubes.
64|
Centrifuge the samples at 16,000g for 20 min at 4 °C.
65|
Wash the samples with 1 ml of 70% (vol/vol) ethanol twice.
66| Air-dry the pellets for 3 min at room temperature.  crItIcal step The first-round pellet should be bigger than the second-round pellet.
67|
Dissolve the pellets in 6 µl of fresh nuclease-free water, and combine the first-and second-round elution samples. Now the total volume is 12 µl. Place the samples on ice.
68|
Measure the RNA concentration of samples by Nanodrop or Qubit assay.  crItIcal step Nanodrop gives an overestimated concentration. Normally, 30-60 ng/µl RNA will be collected by this method (from HeLa cells).
? troublesHootInG  pause poInt The RNA samples can be stored for several weeks at −80 °C. Step 95, the number of PCR cycles can be changed by returning to this step and repeating the procedure with the remaining sample.
82|
Heat the tube for 2 min at 70 °C, and immediately after heating place it on ice.
83| Prepare the reverse transcription reaction mixture tabulated below, mix it well by pipetting, and add 5.5 µl of the mix to each tube from Step 82. antIcIpateD results mNET-seq generates paired-end sequence data corresponding to Pol II immunoprecipitated protein-protected RNA fragments from which Pol II occupancy can be determined. By using different Pol II antibodies, Pol II modification-specific nascent RNA can be profiled at single-nucleotide resolution. mNET-seq with total Pol II-specific antibody CMA601 should generate a fully engaged Pol II profile (supplementary Fig. 1 ). In addition, a Ser5-P CTD-specific antibody, such as CMA603, should detect peaks at the 3′ end of exons, which are derived from splicing. Important quality control checkpoints in the mNET-seq protocol are described below.
rna recovery (steps 50 and 68)
For a typical mNET-seq experiment using eight 150-mm plates of near-confluent HeLa cells (~10 8 cells) and immunoprecipitated with Pol II-specific antibody, the radiolabeled RNA should give a reading of >2,000 c.p.s. (Geiger reading). However, levels will depend on the number and type of cells, the type of antibody used and how fresh the γ-32 P ATP is. If signals are lower than 2,000 c.p.s., then check the Pol II IP efficiency and the working environment, which should be RNase-free. For details, see Troubleshooting Table. Typically, 0.5-2 µg of RNA can be recovered after gel purification; 150 ng of RNA is sufficient to generate mNET-seq cDNA library.
mnet-seq cDna library preparation (steps 69-95)
150-400 ng of RNA is recommended as a starting point for cDNA library preparation. After cDNA amplification and gel purification of 150-to 230-bp PCR product, 0.5-2 µg of PCR library can be expected. For best results from high-throughput sequencing, submit 1-2 µg per library. Figure 3 shows representative profiles from a successful mNET-seq experiment. This example shows mNET-seq profiles of the salt inducible kinase 1 (SIK1) gene using four different Pol II-specific antibodies that detect the Pol II active site RNA and RNA processing intermediates. The mNET-seq profiles are compared with a chromatin-bound RNA sequencing (ChrRNA-seq) profile that was used as an input for mNET-seq. Signals are observed across the gene. For 8WG16 unphosphorylated CTD (Unph), higher mNET-seq reads are detectable over the TSS, whereas for CMA603 Ser5-P CTD (S5P), specific peaks are detected at the 3′ end of exons, which are known splicing intermediates. Note that strong signals are detected downstream of the transcription end site (TES, also referred to as the polyA site), which reflect Pol II pausing associated with termination 13 . (table 2) , CMA601 (Total), 8WG16 unphosphorylated CTD (Unph), CMA602 Ser2-P CTD (S2P) and CMA603 Ser5-P CTD (S5P), were used for the mNET-seq. The RNA from the chromatin fraction was also sequenced (ChrRNA-seq, bottom). mNET-seq detects the 3′ end of nascent RNA across the SIK1 gene and also downstream of the TES. CMA603 specifically immunoprecipitated 5′SS cleaved splicing intermediates.
Unsuccessful experiments caused by low read count or quality may result in insufficient mapping of reads to the genome or incorrect read pairing. This will generate gene profiles with low read counts, and the features described above will be absent or barely detectable.
background levels in mnet-seq analysis
To understand the ability of mNET-seq protocol to specifically target nascent Pol II transcripts, we compared the sense signal of a set of expressed protein-coding genes with that of rRNA-and tRNA-producing genes, which are transcribed by RNA polymerase I and RNA polymerase III, respectively (supplementary Fig. 2) . We show that the coverage of protein-coding genes is significantly higher when compared with the other two groups (two-sided Mann-Whitney U test: P < 2.2e−16 for both). In addition, we also compared the genome-wide coverage of total Pol II mNET-seq to GRO-seq data (supplementary Fig. 1) . By dividing the genome in 500-kb bins, the coverage of these samples shows a very high positive correlation (Pearson's correlation coefficient = 0.93, P < 2.2e−16). Together, these results attest to the low unspecific background levels generated by the mNET-seq protocol.
